Expertise in
28
conditions

Marco Cattalini

Brescia, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
28
conditions
Brescia, IT 

Overview

Marco Cattalini practices practicing medicine in Brescia, Italy.

Mr. Cattalini is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Aicardi-Goutieres Syndrome, Juvenile Idiopathic Arthritis (JIA), TNF Receptor-Associated Periodic Syndrome, and Uveitis.

He is actively involved in clinical research, co-authoring 134 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Brescia, Italy
Other Locations
Pavia, Italy
Genoa, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Ixekizumab, Adalimumab
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 3 Less Clinical Trials

134 Total Publications

Domains and outcome measures for the assessment of cardiac involvement in juvenile systemic sclerosis: a scoping literature review.
Domains and outcome measures for the assessment of cardiac involvement in juvenile systemic sclerosis: a scoping literature review.
Journal: Clinical and experimental rheumatology
Published: July 07, 2026

Frequently Asked Questions about Marco Cattalini

Is Marco Cattalini a top-rated expert for Aicardi-Goutieres Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Marco Cattalini is classified as an Distinguished expert for Aicardi-Goutieres Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marco Cattalini participate in research or clinical trials?

Yes. Marco Cattalini has published 134 articles and abstracts on conditions like Aicardi-Goutieres Syndrome. You can view a list of Marco Cattalini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cattalini's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile